: Thermo Fisher buying CorEvitas for $912.5 mln

Thermo Fisher Scientific Inc. TMO said Thursday it agreed to pay $912.5 million in cash for Waltham, Mass.-based CorEvitas LLC, a provider of “regulatory-grade” evidence for approved medical treatments and therapies, from seller Audax Private Equity. Thermo Fisher said the acquisition of the 300-employee company with $110 million in projected 2023 revenue will add 3 cents a share to Thermo Fisher’s adjusted 2024 earnings. Thermo Fischer CEO Marc N. Casper said, “There is strong market demand for real-world evidence which improves decision making and reduces the time and cost associated with drug development.” The deal is expected to close by the end of 2023.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.